Efficacy of transoral fundoplication for treatment of chronic gastroesophageal reflux disease incompletely controlled with high-dose proton-pump inhibitors therapy: a randomized, multicenter, open label, crossover study

Karim Sami Trad, Gilbert Simoni, William Edris Barnes, Ahmad Bassel Shughoury, Mamoon Raza, Jeffrey Alan Heise, Daniel Gilles Turgeon, Mark Alan Fox, Peter George Mavrelis, Karim Sami Trad, Gilbert Simoni, William Edris Barnes, Ahmad Bassel Shughoury, Mamoon Raza, Jeffrey Alan Heise, Daniel Gilles Turgeon, Mark Alan Fox, Peter George Mavrelis

Abstract

Background: The aim of this randomized, crossover study was to determine if transoral fundoplication (TF) could further improve clinical outcomes in partial responders to high-dose (HD) proton-pump inhibitor (PPI) therapy and to evaluate durability of TF.

Methods: In seven United States centers, patients with hiatal hernia ≤ 2 cm and abnormal esophageal acid exposure (EAE) were randomized to TF (n = 40) or HD PPIs (n = 23) group. At 6-month follow-up, PPI patients underwent crossover. We assessed clinical outcomes 6-month post TF in crossover patients (COP), as compared to 6-month of HD PPI therapy, and 12-month outcomes in patients initially randomized to TF. The primary outcome was symptom control evaluated by Reflux Disease Questionnaire and Reflux Symptom Index. Secondary outcomes included healing of esophagitis, normalization of EAE and PPI use after TF. We analyzed 21 COP and 39 TF patients. McNemar's test or Fisher exact test was used to compare proportions.

Results: Of 63 randomized patients, 3 were lost to follow-up, leaving 39 TF and 21 COP for analyses. In the COP, TF further improved control of regurgitation and of atypical symptoms achieved after six months of HD PPIs. Of 20 patients with GERD symptoms after six months of high-dose PPI therapy, 65% (13/20) reported global elimination of troublesome regurgitation and atypical symptoms post TF off PPIs; 67% (6/9) reported no troublesome regurgitation. Esophagitis further healed in 75% (6/8) of patients. Seventy-one percent of COP patients were off PPIs six months following TF. Normalization of EAE decreased from 52% after HD PPIs (on PPIs) to 33% after TF (off PPIs), p =0.388. In the original TF group, 12-month post TF, 77% of patients achieved complete symptom control, 82% ceased PPI therapy, 100% healed esophagitis and 45% normalized EAE.

Conclusions: The results of this study indicate that in patients with incomplete symptom control on high-dose PPI therapy TF may provide further elimination of symptoms and esophagitis healing. In the original TF group, the clinical outcomes of TF remained stable between 6- and 12-month follow-up.

Trial registration: ClinicalTrials.gov NCT01647958.

Figures

Figure 1
Figure 1
CONSORT diagram of the study.
Figure 2
Figure 2
Proton pump inhibitors use (A and B), healing of reflux esophagitis (C and D) and normalization of esophageal acid exposure (E and F) in both treatment groups at different study intervals.

References

    1. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500–1511. doi: 10.1053/gast.2002.32978.
    1. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58(2):295–309. doi: 10.1136/gut.2007.145581.
    1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, and the Global Consensus Group The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;10(8):1900–1920. doi: 10.1111/j.1572-0241.2006.00630.x.
    1. Anvari M, Allen C, Marshall J, Armstrong D, Goeree R, Ungar W, Goldsmith C. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal reflux disease: one-year follow-up. Surg Innov. 2006;13(4):238–249. doi: 10.1177/1553350606296389.
    1. Ciovica R, Gadenstatter M, Klingler A, Lechner W, Riedl O, Schwab GP. Quality of life in GERD patients: medical treatment versus antireflux surgery. J Gastrointest Surg. 2006;10(7):934–939. doi: 10.1016/j.gassur.2006.04.001.
    1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–328. doi: 10.1038/ajg.2012.444.
    1. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106(8):1419–1425. doi: 10.1038/ajg.2011.146.
    1. Dunkin B, Eubanks S, Marks J, Marohn M, Park A, Pryor A, Ponsky J, Rattner D, Rosenthal R, Shah P, Smith CD, Soper N, Swanstrom L, Thaler K. Position statement on endoluminal therapies for gastrointestinal diseases. 2009.
    1. Wendling MR, Melvin WS, Perry KA. Impact of transoral incisionless fundoplication (TIF) on subjective and objective GERD indices: a systematic review of the published literature. Surg Endosc. 2013;27(10):3754–3761. doi: 10.1007/s00464-013-2961-0.
    1. Trad KS, Barnes WE, Simoni G, Shughoury AB, Mavrelis PG, Raza M, Heise JA, Turgeon DG, Fox MA. Surg Innov. 2014. Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO randomized clinical trial.
    1. Hirano I, Richter JE, Practice Committee of the American College of Gastroenterology ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102(3):668–685. doi: 10.1111/j.1572-0241.2006.00936.x.
    1. Lundell LR, Dent J, Bennett JR, Blum AL, Amstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172–180. doi: 10.1136/gut.45.2.172.
    1. Hill LD, Kozarek RA, Kraemer SJ, Aye RW, Mercer CD, Low DE, Pope CE., II The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc. 1996;44(5):541–547. doi: 10.1016/S0016-5107(96)70006-8.
    1. Oberg S, Peters JH, DeMeester TR, Lord RV, Johansson J, Crookes PF, Bremner CG. Endoscopic grading of the gastroesophageal valve in patients with symptoms of gastroesophageal reflux disease (GERD) Surg Endosc. 1999;13(12):1184–1188. doi: 10.1007/PL00009617.
    1. Bell RCW, Cadiere GB. Transoral rotational esophago-gastric fundoplication: technical, anatomical, and safety consideration. Surg Endosc. 2011;25(7):2387–2399. doi: 10.1007/s00464-010-1528-6.
    1. Oridate N, Takeda H, Asaka M, Nishizawa N, Mesuda Y, Mori M, Furuta Y, Fukuda S. Acid-suppression therapy offers varied laryngopharyngeal and esophageal symptom relief in laryngopharyngeal reflux patients. Dig Dis Sci. 2008;53(8):2033–2038. doi: 10.1007/s10620-007-0114-9.
    1. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, Vlahcevic ZR, Young R, Williford W. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285(18):2331–2338. doi: 10.1001/jama.285.18.2331.
    1. Velanovich V, Karmy-Jones R. Measuring gastroesophageal reflux disease: relationship between the health-related quality of life score and physiologic parameters. Am Surg. 1998;64(7):649–653.
    1. Markus PM, Horstmann O, Kley C, Neufang T, Becker H. Laparoscopic fundoplication. Surg Endosc. 2002;16(1):48–53. doi: 10.1007/s00464-001-9054-1.
    1. Milkes D, Gerson LB, Triadafilopoulus G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD) Am J Gastroenterol. 2004;99(6):991–996. doi: 10.1111/j.1572-0241.2004.30124.x.
    1. Lin D, Triadafilopoulus G. Dig Dis Sci. 2014. Dual ambulatory pH monitoring in patients with gastroesophageal reflux rendered asymptomatic with proton pump inhibitor therapy.
    1. Rinsma NF, Smeets FG, Bruls DW, Kessing BF, Bouvy ND, Masclee AA, Conchillo JM. Effects of transoral incisionless fundoplication on reflux mechanisms. Surg Endosc. 2014;28(3):941–949. doi: 10.1007/s00464-013-3250-7.
    1. Cadiere GB, Buset M, Muls V, Rajan A, Rosch T, Eckardt AJ, Weerts J, Bastens B, Costamagna G, Marchese M, Louis H, Mana F, Sermon F, Gawlicka AK, Daniel MA, Deviere J. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg. 2008;32(8):1676–1688. doi: 10.1007/s00268-008-9594-9.
    1. Testoni PA, Corsetti M, Di Pietro S, Castellaneta AG, Vailati C, Masci E, Passaretti S. Effect of transoral incisionless fundoplication on symptoms, PPI use, and ph-impedance refluxes of GERD patients. World J Surg. 2010;34(4):750–757. doi: 10.1007/s00268-010-0394-7.
    1. Bell RCW, Mavrelis PG, Barnes WE, Dargis D, Carter BJ, Hoddinott KM, Sewell RW, Trad KS, DaCosta GB, Ihde GM. A prospective multicenter registry of patients with chronic gastroesophageal reflux disease receiving transoral incisionless fundoplication. J Am Coll Surg. 2012;215(6):794–809. doi: 10.1016/j.jamcollsurg.2012.07.014.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit